Related Experiment Videos
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes
1Department of Pharmacology, University of Bologna, Italy. deponti@biocfarm.unibo.it
Drugs
|April 11, 2001
Summary
Research explores serotonin receptor ligands for irritable bowel syndrome (IBS) treatment. Targeting 5-HT3 and 5-HT4 receptors shows promise for managing IBS symptoms like pain, diarrhea, and constipation.
Area of Science:
- Gastroenterology
- Pharmacology
- Neurogastroenterology
Background:
- Functional gastrointestinal disorders, particularly irritable bowel syndrome (IBS), have seen limited drug approvals despite numerous compound developments.
- Traditional IBS drug development focused on gastrointestinal (GI) motility, but altered visceral sensitivity is now a recognized therapeutic target.
- Serotonin (5-hydroxytryptamine; 5-HT) plays a crucial role in GI function and visceral sensitivity, making its receptors key targets for IBS treatment.
Purpose of the Study:
- To review the current landscape of compounds targeting serotonin receptors for irritable bowel syndrome (IBS) treatment.
- To discuss the role of different serotonin receptor subtypes (5-HT3, 5-HT4, 5-HT7, 5-HT(1B/D)) in IBS pathophysiology and therapeutic potential.
- To highlight emerging drug candidates and their specific indications within IBS subpopulations.
Main Methods:
- Literature review of preclinical and clinical studies on serotonin receptor ligands in IBS.
- Analysis of the mechanisms of action for various serotonin receptor antagonists and agonists.
- Examination of efficacy and safety data for compounds targeting specific IBS subtypes (diarrhea-predominant or constipation-predominant).
Main Results:
- 5-HT3 receptor antagonists, like alosetron, showed efficacy in diarrhea-predominant IBS but faced safety concerns.
- 5-HT4 receptor agonists (e.g., tegaserod, prucalopride) are being developed for hypomotility targets and may also modulate visceral sensitivity.
- Emerging research focuses on 5-HT7 and 5-HT(1B/D) receptors for their roles in smooth muscle relaxation and visceral sensitivity modulation.
Conclusions:
- Serotonin receptor modulation offers a promising therapeutic avenue for irritable bowel syndrome (IBS) by addressing motility and visceral sensitivity.
- Development of subtype-specific ligands is crucial for targeted IBS treatment, particularly for diarrhea- or constipation-predominant forms.
- Continued research into novel serotonin receptor targets is essential for advancing IBS pharmacotherapy and improving patient outcomes.